非酒精性脂肪性肝病患者血清SFRP5水平與血脂相關(guān)性分析
發(fā)布時(shí)間：2018-08-19 07:32
【摘要】：背景：非酒精性脂肪性肝病(Non-alcoholic fatty liver disease, NAFLD)是除外酒精和其它明確的肝損害因素所致的,以肝臟細(xì)胞內(nèi)脂肪變?yōu)橹饕卣鞯穆愿闻K疾病,一逐漸成為我國及西方國家常見的慢性肝臟疾病。分泌型卷曲相關(guān)蛋白5(Secreted frizzled-related protein 5, SFRP5)是一種能內(nèi)源性抑制Wnt信號通路的抗炎脂肪因子,近年來SFRP5在許多代謝性疾病如2型糖尿病、肥胖、冠心病中的表達(dá)及意義均有較多研究。越來越多的研究表明NAFLD與肥胖、2型糖尿病、胰島素抵抗、高脂血癥、心血管疾病密切相關(guān),而SFRP5在NAFLD中的表達(dá)情況及其與血脂等因素的相關(guān)性國內(nèi)外尚無相關(guān)研究。目的：探討SFRP5在非酒精性脂肪性肝病血清中的表達(dá)水平及其與血脂等相關(guān)影響因素的關(guān)系。方法；收集2013年10月-2014年7月重慶醫(yī)科大學(xué)附屬第二醫(yī)院診斷為NAFLD患者58人作為實(shí)驗(yàn)組,體檢中心健康體檢者58人作為對照組(NC),根據(jù)腹部超聲表現(xiàn)由有經(jīng)驗(yàn)的兩名超聲科醫(yī)生將肝臟脂肪變程度分為輕、中、重度,根據(jù)脂肪變程度將NAFLD組分為三亞組。于重慶醫(yī)科大學(xué)附屬第二醫(yī)院檢驗(yàn)科測定空腹血糖(FastingPlasma Glucose, FPG)、糖化血紅蛋白(HBAlc)、總膽固醇(Total Cholesterol, TC)、甘油三酯(Triglyceride, TG)、高密度脂蛋白(High-density lipoprotein, HDL)、低密度脂蛋白(Low density lipoprotein, LDL)、游離脂肪酸(Free fatty acid, FFA)、載脂蛋白B (Apolipoprotein B, ApoB)、尿酸(Uricacid)、谷丙轉(zhuǎn)氨酶(Alanine aminotransf erase, ALT)、谷草轉(zhuǎn)氨酶(Aspartate aminotransf erase,AST)、堿性磷酸酶(Alkaline phosphatase, ALP)、谷氨酰轉(zhuǎn)肽酶(Gamma-glutamyl transpeptidase, y -GGT)、總膽紅素(Total bilirubin, TB)、結(jié)合膽紅素(Conjugated bilirubin, CB)、非結(jié)合膽紅素(Unconjugated bilirubin, UCB)、凝血酶原活動(dòng)度(Prothrombin activity, PTA)水平；采用ELISA法檢測血清SFRP5水平,分析NAFLD患者中SFRP5與血脂及其他影響因素的相關(guān)性。結(jié)果：與NC組相比,NAFLD組的BMI、SBP、DBP、HbA1c、TG、TC、LDL-C, ApoB、Uric acid、ALT、AST、γ-GGT, SFRP5水平明顯升高(P0.05或P0.01,)；Pearson相關(guān)分析顯示,血清SFRP5與TC、HDL-C、ApoB呈負(fù)相關(guān)性(P0.05或P0.01)；Spearman相關(guān)分析顯示,血清SFRP5與肝臟脂肪變呈正相關(guān)性(P=0.029,r=0.287)；多元線性回歸顯示,TC是SFRP5的獨(dú)立影響因素。結(jié)論：SFRP5在非酒精性脂肪性肝病中升高且與肝臟脂肪變呈正相關(guān)性,與TC呈負(fù)相關(guān),提示在對抗肝臟脂肪沉積、代謝應(yīng)激、胰島素抵抗等存在急性或慢性代償機(jī)制,可能參與延緩非酒精脂肪性肝病的發(fā)展。
[Abstract]:BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by intracellular fatty degeneration of the liver, which is caused by alcohol and other specific liver damage factors. It has gradually become a common chronic liver disease in China and Western countries. Secret-related protein 5 (Secret-5) Ed frizzled-related protein 5 (SFRP5) is an endogenous anti-inflammatory adipokine that inhibits the Wnt signaling pathway. In recent years, the expression and significance of SFRP5 in many metabolic diseases such as type 2 diabetes mellitus, obesity, coronary heart disease have been studied. Objectives: To investigate the expression of SFRP5 in non-alcoholic fatty liver disease (NAFLD) serum and its relationship with blood lipids and other related factors. Fifty-eight patients with NAFLD diagnosed in the Second Affiliated Hospital of the University were selected as the experimental group and 58 healthy people as the control group (NC). According to the abdominal ultrasound findings, two experienced ultrasound doctors divided the degree of liver fatty degeneration into mild, moderate and severe groups. The NAFLD group was divided into three subgroups according to the degree of fatty degeneration. Fasting plasma Glucose (FPG), glycosylated hemoglobin (HBAlc), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), free fatty acid (FFA), were measured in the Laboratory Department of the Second Hospital. Apolipoprotein B (ApoB), Uricacid, Alanine aminotransf erase (ALT), Aspartate aminotransf erase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (y-GGT), Total bilirubin (TB), and Binding Bile Conjugated bilirubin (CB), Unconjugated bilirubin (UCB) and prothrombin activity (PTA) were measured. Serum SFRP5 levels were measured by ELISA to analyze the correlation between SFRP5 and blood lipids and other influencing factors in NAFLD patients. Results: Compared with NC group, BMI, SBP, DBP, HbA1c, TG in NAFLD group were detected. TC, LDL-C, ApoB, Uric acid, ALT, AST, gamma-GGT, SFRP5 levels significantly increased (P 0.05 or P 0.01,); Pearson correlation analysis showed that serum SFRP5 and TC, HDL-C, ApoSpearman correlation analysis showed that serum SFRP5 and liver steatosis were positively correlated (P = 0.029, r = 0.287); multiple linear regression analysis showed that SFRP5 was a negative correlation (P 0.05 or P 0.01); serum SFRP5 was positively correlated with liver steatosis (P = 0.029, r = 0.287). Conclusion: SFRP5 is elevated in non-alcoholic fatty liver disease and positively correlated with hepatic steatosis, and negatively correlated with TC, suggesting that there are acute or chronic compensatory mechanisms against liver fat deposition, metabolic stress and insulin resistance, which may be involved in delaying the development of non-alcoholic fatty liver disease.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R575.5
本文編號：2191079
[Abstract]:BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by intracellular fatty degeneration of the liver, which is caused by alcohol and other specific liver damage factors. It has gradually become a common chronic liver disease in China and Western countries. Secret-related protein 5 (Secret-5) Ed frizzled-related protein 5 (SFRP5) is an endogenous anti-inflammatory adipokine that inhibits the Wnt signaling pathway. In recent years, the expression and significance of SFRP5 in many metabolic diseases such as type 2 diabetes mellitus, obesity, coronary heart disease have been studied. Objectives: To investigate the expression of SFRP5 in non-alcoholic fatty liver disease (NAFLD) serum and its relationship with blood lipids and other related factors. Fifty-eight patients with NAFLD diagnosed in the Second Affiliated Hospital of the University were selected as the experimental group and 58 healthy people as the control group (NC). According to the abdominal ultrasound findings, two experienced ultrasound doctors divided the degree of liver fatty degeneration into mild, moderate and severe groups. The NAFLD group was divided into three subgroups according to the degree of fatty degeneration. Fasting plasma Glucose (FPG), glycosylated hemoglobin (HBAlc), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), free fatty acid (FFA), were measured in the Laboratory Department of the Second Hospital. Apolipoprotein B (ApoB), Uricacid, Alanine aminotransf erase (ALT), Aspartate aminotransf erase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (y-GGT), Total bilirubin (TB), and Binding Bile Conjugated bilirubin (CB), Unconjugated bilirubin (UCB) and prothrombin activity (PTA) were measured. Serum SFRP5 levels were measured by ELISA to analyze the correlation between SFRP5 and blood lipids and other influencing factors in NAFLD patients. Results: Compared with NC group, BMI, SBP, DBP, HbA1c, TG in NAFLD group were detected. TC, LDL-C, ApoB, Uric acid, ALT, AST, gamma-GGT, SFRP5 levels significantly increased (P 0.05 or P 0.01,); Pearson correlation analysis showed that serum SFRP5 and TC, HDL-C, ApoSpearman correlation analysis showed that serum SFRP5 and liver steatosis were positively correlated (P = 0.029, r = 0.287); multiple linear regression analysis showed that SFRP5 was a negative correlation (P 0.05 or P 0.01); serum SFRP5 was positively correlated with liver steatosis (P = 0.029, r = 0.287). Conclusion: SFRP5 is elevated in non-alcoholic fatty liver disease and positively correlated with hepatic steatosis, and negatively correlated with TC, suggesting that there are acute or chronic compensatory mechanisms against liver fat deposition, metabolic stress and insulin resistance, which may be involved in delaying the development of non-alcoholic fatty liver disease.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R575.5
【相似文獻(xiàn)】
相關(guān)期刊論文 前1條
1 史曉紅;范蕓;周昌虎;寧尚勇;孫亮;朱小泉;唐雷;常乃柏;楊澤;;骨髓增生異常綜合征患者SFRP5基因啟動(dòng)子區(qū)甲基化狀態(tài)研究[J];中國組織工程研究與臨床康復(fù);2011年14期
相關(guān)碩士學(xué)位論文 前1條
1 康冰;非酒精性脂肪性肝病患者血清SFRP5水平與血脂相關(guān)性分析[D];重慶醫(yī)科大學(xué);2015年
，本文編號：2191079
本文鏈接：http://sikaile.net/yixuelunwen/xiaohjib/2191079.html
最近更新
教材專著
